This evidence indicates that Nr4a1 is responsible for defects caused by SNRPN knockdown and that pharmacological inhibition of Nr4a1 is a potential therapeutic target for SNRPN-related brain disorders. This evidence concerns the gene SNRPN and brain disorder.